Ipamorelin
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Ipamorelin is listed as endocrine / ghrp.
- •GH secretagogue
- •Sleep optimization
- •Body composition
- •Anti-aging
Regulatory status: Not FDA-approved; compounded/research use.
Structure & Properties
Compound: Ipamorelin; also known as NNC 26-0161.
Pharmacologic class: Endocrine / GHRP.
Known delivery routes: Subcutaneous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Selective ghrelin / GHS-R1a agonist — stimulates pituitary GH release without significantly raising cortisol or prolactin; clean pulse profile.
- •Selective GH release with minimal cortisol/prolactin rise
- •Improved sleep depth
- •Pairs synergistically with Mod GRF 1-29
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Phase I/II (discontinued); robust animal data
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
1–3× daily on an empty stomach. Best pulses: 30 min pre-bed (aligns with natural GH surge), post-workout, and/or fasted morning. Wait 30 min before eating.
Potential interactions and combinations to avoid
- •GHRP-2, GHRP-6, Hexarelin — same receptor class, additive without benefit
- •MK-677 chronically — persistent ghrelin activation
- •Meals within 30 min of injection
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Mild hunger
- •Possible IGF-1 elevation
- •Theoretical neoplasia risk
Contraindications
- •Active malignancy
- •Pregnancy
- •Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- •Active or untreated diabetic retinopathy
- •Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- •Untreated hypothyroidism or uncorrected adrenal insufficiency
- •Acromegaly, pituitary adenoma, or intracranial hypertension
- •Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- •Critical illness after acute surgery, trauma, or respiratory failure
- •Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 100–300 mcg/dose
Frequency: 1–3× daily; ideally fasted or pre-sleep
Cycling: 8–12 weeks on / 4 weeks off.
Subcutaneous (SubQ)
Default route for most research and therapeutic peptides — best absorption for reconstituted powder.
31G × 5/16" insulin syringe (U-100). 100 units = 1 mL. Pinch skin at abdomen (2" from navel), outer thigh, or love handle. Insert at 45–90°. Rotate sites daily to prevent lipohypertrophy. Alcohol-swab site, air-dry, inject slow, hold 5 sec.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •CJC-1295 (with or without DAC) — GHRH + GHRP synergy is the classic stack
- •BPC-157 / TB-500 for recovery
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
30 minutes before bed on an empty stomach; a fasted morning or post-workout dose is optional.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Flank / love handle — Lateral fat pad above the hip. Good rotation site when the abdomen is tender.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
8–12 weeks on / 4 weeks off.
Timing & Interactions
- ·GHRP-2, GHRP-6, Hexarelin — same receptor class, additive without benefit
- ·MK-677 chronically — persistent ghrelin activation
- ·Meals within 30 min of injection
- ·CJC-1295 (with or without DAC) — GHRH + GHRP synergy is the classic stack
- ·BPC-157 / TB-500 for recovery
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Ipamorelin and sync them to Vial Lab.
Benefits
- ·Selective GH release with minimal cortisol/prolactin rise
- ·Improved sleep depth
- ·Pairs synergistically with Mod GRF 1-29
Risks
- ·Mild hunger
- ·Possible IGF-1 elevation
- ·Theoretical neoplasia risk
Contraindications
- ·Active malignancy
- ·Pregnancy
- ·Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- ·Active or untreated diabetic retinopathy
- ·Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- ·Untreated hypothyroidism or uncorrected adrenal insufficiency
- ·Acromegaly, pituitary adenoma, or intracranial hypertension
- ·Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- ·Critical illness after acute surgery, trauma, or respiratory failure
- ·Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Not FDA-approved; compounded/research use
Veterinary Use (Pets)
Used off-label to support recovery, appetite, and sleep quality in performance dogs and horses.
Functional Groups
Cited Works
Tap any study to open the published work.